Suppr超能文献

高级模态探索:不可切除但局限于肝内的肝细胞癌患者接受亚分次图像引导调强放疗的安全性和疗效。

Exploration of Superior Modality: Safety and Efficacy of Hypofractioned Image-Guided Intensity Modulated Radiation Therapy in Patients with Unresectable but Confined Intrahepatic Hepatocellular Carcinoma.

机构信息

Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

出版信息

Can J Gastroenterol Hepatol. 2017;2017:6267981. doi: 10.1155/2017/6267981. Epub 2017 Oct 1.

Abstract

PURPOSE

To evaluate the efficacy and safety of hypofractioned image-guided intensity modulated radiation therapy (IG-IMRT) for unresectable but confined intrahepatic hepatocellular carcinoma in comparison with conventional 3-dimensional conformal radiotherapy (3D-CRT).

METHODS

Ninety patients with unresectable but confined intrahepatic hepatocellular carcinoma without distant metastasis and tumor thrombosis received external beam radiation therapy. Of these patients, 45 received IG-IMRT and 45 received 3D-CRT. The IG-IMRT design delivered a median total hypofractionated dose of 54 Gy (2.2-5.5 Gy/fx), and 3D-CRT delivered a median total dose of 54 Gy with a conventional fraction (2.0 Gy/fx). The clinical response, overall survival, and side effects were analyzed.

RESULTS

The IG-IMRT group showed significantly higher 1-year survival (93.3 versus 77.8%) and 2-year survival (73.3 versus 51.1%) and longer median survival (44.7 versus 24.0 months) than the 3D-CRT group. Multivariate analysis indicated that the patients with intrahepatic tumors smaller than 8 cm, prior TACE before RT, and IG-IMRT would have a survival benefit. There were no significant differences in the rates of side effects between the two groups.

CONCLUSION

Hypofractioned IG-IMRT could improve the therapeutic response and confer a potential survival of patients with unresectable but confined intrahepatic hepatocellular carcinoma compared to 3D-CRT with acceptable toxicity.

摘要

目的

评估适形调强放疗(IG-IMRT)与常规三维适形放疗(3D-CRT)治疗不可切除但局限于肝内的肝细胞癌的疗效和安全性。

方法

90 例无远处转移和肿瘤血栓形成的不可切除但局限于肝内的肝细胞癌患者接受外照射放疗。其中 45 例接受 IG-IMRT,45 例接受 3D-CRT。IG-IMRT 设计给予中位总分割剂量 54Gy(2.2-5.5Gy/fx),3D-CRT 给予常规分割剂量 54Gy(2.0Gy/fx)。分析临床反应、总生存率和副作用。

结果

IG-IMRT 组 1 年生存率(93.3%比 77.8%)、2 年生存率(73.3%比 51.1%)和中位总生存时间(44.7 比 24.0 个月)均显著高于 3D-CRT 组。多因素分析表明,肿瘤直径<8cm、放疗前 TACE、IG-IMRT 的患者生存获益。两组不良反应发生率无显著差异。

结论

与 3D-CRT 相比,低分割 IG-IMRT 可提高不可切除但局限于肝内的肝细胞癌患者的治疗反应,并具有潜在的生存获益,毒性可接受。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70f2/5643031/6351b96090e1/CJGH2017-6267981.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验